News

Drug for ‘hidden’ arthritis to be subsidised from December


Paul Hayes


4/10/2018 1:22:50 PM

Australians with severe inflammatory spinal arthritis will be able to access a vital drug for less than $40 – instead of $1300 – when it is listed on the Pharmaceutical Benefits Scheme from 1 December.

Active non-radiographic axial spondyloarthritis typically affects young adults and includes symptoms similar to a sporting injury.
Active non-radiographic axial spondyloarthritis typically affects young adults and includes symptoms similar to a sporting injury.

Federal Health Minister Greg Hunt said the Government’s move to subsidise golimumab means people with active non-radiographic axial spondyloarthritis will save up to $15,000 a year.
 
‘Patients who would have had to pay over $1300 per script will only pay a maximum of $39.50 per script, or only $6.40 if they have a concession card,’ Minister Hunt said.
 
The condition, often called a hidden form of arthritis, usually affects young adults and can remain undiagnosed for years. It causes back pain, fatigue and stiffness, the damage from which is progressive and irreversible.
 
‘Over time, permanent damage to spinal mobility and function occurs,’ Minister Hunt said.
 
According to Minister Hunt, golimumab can help to reduce inflammation, swelling and joint destruction by blocking inflammation through changes to the patient’s immune system.
 
‘The medication will be of particular benefit to patients who are no longer able to relieve the inflammation and pain using conventional non-steroidal anti-inflammatory drugs,’ he said.
 
‘This listing will save families thousands of dollars and help patients manage their condition and improve their quality of life.’



arthritis golimumab inflammatory spinal arthritis



Login to comment

peter   16/09/2019 6:55:34 PM

need this now hope it works


Comments



 Security code